Genotypic Resistance Guided Therapy in Helicobacter Pylori Eradication

Phase 4 Unknown 450 enrolled National Taiwan University Hospital National Science and Technology Council, Taiwan · collab

RandomizedParallel-groupOpen-labelTreatment

Summary

We aimed to compare the efficacy of genotypic resistance guided sequential therapy vs. empiric therapy in the third line therapy. Factors affecting the eradication rates, including the antibiotic resistance, CYP2C19 polymorphism, CagA and VacA status will also be assessed.

Timeline

Start: 2012-11
Primary completion: 2017-05
Completion: 2017-12

Publications

Liou JM, Chen PY, Luo JC, Lee JY, Chen CC, Fang YJ, Yang TH, Chang CY, Bair MJ, Chen MJ, Hsu YC, Hsu WF, Chang CC, Lin JT, Shun CT, El-Omar EM, Wu MS; Taiwan Gastrointestinal Disease and Helicobacter Consortium. Efficacies of Genotypic Resistance-Guided vs Empirical Therapy for Refractory Helicobacter pylori Infection. Gastroenterology. 2018 Oct;155(4):1109-1119. doi: 10.1053/j.gastro.2018.06.047. Epub 2018 Jun 30.

Drugs

Evaluation	Drug	Modality	Dose	Route
Background	Amoxicillin	Other / unclassified	1 g	—
Background	Esomeprazole	Small molecule	40 mg	—
Background	Metronidazole	Small molecule	500 mg	—

Indications

No indication recorded.